Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$166.4MCash on Hand
14.2mo Cash Runway
0%Short Interest
$45.84Analyst Target (10)
Follow HELP by emailGet an email when HELP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HELP, unsubscribe in one click. Privacy
📣 What HELP Says Is Next
4Q 2027 · “The Company expects to report topline results from the EMBRACE trial in 4Q 2027. 2,3 EXTEND is the ongoing long-term extension study which will provide additional data on long-term safety, durability of effect, and the potential role of redosing.”
Company press release, Nov 16, 2026 · SEC filing
Q1 2027 · “The Company intends to initiate the Phase 2 HLP004 monotherapy study in Q1 2027. 1,2 HLP005: Advancement toward development candidate selection Helus Pharma’s HLP005 program builds upon the current understanding of the mechanism of action of NSAs and aims to identify key polypharmacological combinations capable of mediating therapeutic effects for target indications.”
Company press release, Nov 16, 2026 · SEC filing
Q4 2026 · “APPROACH has completed enrollment, and the study is on track for topline data readout in Q4 2026. 1,2”
Company press release, Nov 16, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Clinical trial Phase 3 APPROACH study of HLP003 as adjunctive treatment in major depressive disorder met its primary endpoint, with a 7.6 point placebo-adjusted MADRS reduction at Week 6 (p<0.0001). Durable effect at Week 12 showed a 7.0 point reduction (p<0.0001). EMBRACE topline results are expected in 4Q 2027. Form 6-K · SEC filing · Press release
Nov 16, 2026 ·
Earnings Reported Q2 fiscal 2027 net loss of $103.1 million versus $33.7 million a year earlier, with cash of $171.1 million as of September 30, 2026. Michael Halstead was named CEO, and topline Phase 3 APPROACH data for HLP003 is still expected in Q4 2026. Form 6-K · SEC filing · Press release
Nov 16, 2026 ·
Clinical trial Helus Pharma will host a webcast at 8:00 a.m. EDT on November 16, 2026 to present topline results from its Phase 3 APPROACH study of HLP003 in major depressive disorder. The results themselves are not included in this filing. Form 6-K · SEC filing · Press release
Nov 6, 2026 ·
Leadership Co-founders Eric So and Paul Glavine stepped down from their executive and consulting roles but remain on the board. Mark Lawson was appointed independent Chair, and the company still expects Phase 3 APPROACH topline data for HLP003 in Q4 2026. Form 6-K · SEC filing · Press release
Nov 3, 2026 ·
Helus Pharma's CEO Michael Halstead will take part in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 9, 2026 at 3:00 p.m. EDT, webcast live. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Leadership Co-founders Eric So and Paul Glavine stepped down from executive and consulting roles but remain on the Board. Director Mark Lawson was named independent Board Chair, effective immediately, and Eric So was named Chairman Emeritus. Form 6-K · SEC filing · Press release
Oct 21, 2026 ·
Clinical trial Helus Pharma reported at its October 21, 2026 investor presentation that topline data from the APPROACH Phase 3 study of HLP003 for adjunctive major depressive disorder remains on track for Q4 2026. Form 6-K · SEC filing · Press release
Oct 15, 2026 ·
Leadership Helus Pharma appointed Dr. Suresh Durgam, its former Scientific Advisory Board member, to its Board of Directors. Dr. Durgam was previously CMO of Intra-Cellular Therapies. The appointment is subject to Cboe Canada approval. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
HELP holds $166.4M in cash and short-term investments and burns about $35.2M/quarter from operations,
an estimated runway of 14.2 months at that rate (BioRadar estimate, not company guidance).
Share count 21,601,208 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-09-30 filed 2026-10-01
So Eric H. L.
Award (A)
248,000
–
4,713,014
2026-09-30 filed 2026-10-01
Glavine Paul
Award (A)
248,000
–
4,750,191
2026-09-29 filed 2026-10-01
Cavers Greg
Purchase (P)
3,000
$12.91
3,000
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
Get the full HELP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HELP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.